Successful liver transplantation in a patient with budd‐chiari syndrome caused by homozygous factor V leiden

Henkie P. Tan, Jay S. Markowitz, Warren R. Maley, William T. Merritt, Andrew S. Klein – 30 December 2003 – Budd‐Chiari syndrome (BCS) is a rare form of portal hypertension characterized by hepatic venous outflow obstruction. Although hematologic disorders are the most common cause of this syndrome, to date, 30% of the cases have been classified as idiopathic. Resistance to activated protein C caused by factor V Leiden is the most common cause of thrombophilia; its role in the pathogenesis of BCS is now becoming apparent.

Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients

Giuliano Testa, Jeffrey S. Crippin, George J. Netto, Robert M. Goldstein, Linda W. Jennings, Borisa S. Brkic, Barbara K. Brooks, Marlon F. Levy, Thomas A. Gonwa, Goran B. Klintmalm – 30 December 2003 – The time progression of allograft damage in patients with recurrent hepatitis C after orthotopic liver transplantation (OLT) is not precisely determined. The aim of this analysis is to study the progression of disease recurrence and its impact on patient and graft survival.

Liver transplant waiting time does not correlate with waiting list mortality: Implications for liver allocation policy

Richard B. Freeman, Erick B. Edwards – 30 December 2003 – Factors associated with the risk for mortality once placed on the liver transplant waiting list and how this risk relates to center‐specific waiting time and transplant activity have not been adequately evaluated. We performed this study to determine the association between center‐specific waiting time and waiting list mortality among liver transplant candidates stratified by medical urgency at the time of registration.

Persistent cytomegalovirus in liver allografts with chronic rejection

I. Lautenschlager, K. Höckerstedt, H. Jalanko, R. Loginov, K. Salmela, E. Taskinen, J. Ahonen – 30 December 2003 – Cytomegalovirus (CMV) infection is one of the suggested risk factors for chronic allograft rejection. Clinical and experimental studies have shown that CMV is somehow implicated in rejection mechanisms and in the generation of graft arteriosclerosis, characteristic of chronic rejection. In liver transplantation, there is also evidence of an association between CMV and vanishing bile duct‐syndrome (VBDS), which is characteristic of chronic liver allograft rejection.

Preoperative determination of the surgical procedure for hepatectomy using technetium‐99m‐galactosyl human serum albumin (99mTc‐GSA) liver scintigraphy

A Kwon, S K Ha‐Kawa, S Uetsuji, T Inoue, Y Matsui, Y Kamiyama – 30 December 2003 – Technetium‐99m‐diethylenetriaminepentaacetic acidgalactosyl human serum albumin (Tc‐GSA) is a new liver scintigraphy agent which binds to the asialoglycoprotein receptors. We evaluated the preoperative assessment for hepatectomy using Tc‐GSA liver scintigraphy. Ninety patients with hepatocellular carcinoma were admitted for elective hepatectomy.

Type IIIb glycogen storage disease associated with end‐stage cirrhosis and hepatocellular carcinoma

E B Haagsma, G P Smit, K E Niezen‐Koning, A S Gouw, L Meerman, M J Slooff – 30 December 2003 – Type III glycogen storage disease (GSD) is a disorder of carbohydrate metabolism caused by a deficiency of debranching enzyme. Different subtypes with different clinical pictures have been recognized. During childhood and early adulthood, the symptoms generally regress, and normal adulthood appears possible in most patients without symptoms or signs of cirrhosis. We report on an adult patient with GSD who developed endstage cirrhosis and a small hepatocellular carcinoma.

Subscribe to